Abstract:BACKGROUND:Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is usually administered by injection, and its oral administration in a clinical setting has been not yet reported. Here we demonstrate the bioavailability of orally administered rhGM-CSF in healthy volunteers. The rhGM-CSF was expressed in Bombyx mori expression system (BmrhGM-CSF).METHODS AND FINDINGS:Using a single-dose, randomized, open-label, two-period crossover clinical trial design, 19 healthy volunteers were orally administered with BmrhGM-CSF (8 microg/kg) and subcutaneously injected with rhGM-CSF (3.75 microg/kg) respectively. Serum samples were drawn at 0.0h, 0.5h ,0.75h,1.0h,1.5h,2.0h ,3.0h,4.0h,5.0h,6.0h,8.0h,10.0h and 12.0h after administrations. The hGM-CSF serum concentrations were determined by ELISA. The AUC was calculated using the trapezoid method. The relative bioavailability of BmrhGM-CSF was determined according to the AUC ratio of both orally administered and subcutaneously injected rhGM-CSF. Three volunteers were randomly selected from 15 orally administrated subjects with ELISA detectable values. Their serum samples at the 0.0h, 1.0h, 2.0h, 3.0h and 4.0h after the administrations were analyzed by Q-Trap MS/MS TOF. The different peaks were revealed by the spectrogram profile comparison of the 1.0h, 2.0h, 3.0h and 4.0h samples with that of the 0.0h sample, and further analyzed using both Enhanced Product Ion (EPI) scanning and Peptide Mass Fingerprinting Analysis. The rhGM-CSF was detected in the serum samples from 15 of 19 volunteers administrated with BmrhGM-CSF. Its bioavailability was observed at an average of 1.0%, with the highest of 3.1%. The rhGM-CSF peptide sequences in the serum samples were detected by MS analysis, and their sizes ranging from 2,039 to 7,336 Da.CONCLUSIONS:The results demonstrated that the oral administered BmrhGM-CSF was absorbed into the blood. This study provides an approach for an oral administration of rhGM-CSF protein in clinical settings.TRIAL REGISTRATION:www.chictr.orgChiCTR-TRC-00000107.

Pharmacokinetics of recombinant human basic fibroblast growth factor following intravenous bolus plus infusion in rhesus monkey

Toxicokinetics of recombinant human fibroblast growth factor 21 for injection in cynomolgus monkey for 3 months

Gelatin Nanostructured Lipid Carriers-Mediated Intranasal Delivery of Basic Fibroblast Growth Factor Enhances Functional Recovery in Hemiparkinsonian Rats

In Vivo Bioassay of Recombinant Human Growth Hormone Synthesized Inb. Moripupae

Basic Fibroblast Growth Factor Alleviates Brain Injury Following Global Ischemia Reperfusion in Rabbits

Bioavailability of Orally Administered Rhgm-Csf: a Single-Dose, Randomized, Open-Label, Two-Period Crossover Trial.

Pharmacokinetics of Recombinant Human Growth Hormone (rhGH) in Beagles by ELISA

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Pharmacokinetics after a Single Subcutaneous Injection of Recombinant Human Thrombopoietin in Human

Assessment of the Pre-Clinical Immunogenicity of a New VEGF Receptor Fc-fusion Protein FP3 with ELISA and BIACORE.

In Vivo Validation of Biological Responses of Bfgf Released from Microspheres Formulated by Blending Poly-Lactide-co-Glycolide and Poly(ethylene Glycol)-Grafted-chitosan in Hamster Cheek Pouch Microcirculatory Models

Pharmacokinetics of PEG-rhG-CSF and rHSA-hG-CSF in mice determined with ELISA

Pharmacokinetics, Pharmacodynamics, and Bioequivalence Study of SciLin TMR Recombinant Human Insulin Injection Preparation

Surface plasmon resonance analysis to evaluate the importance of heparin sulfate groups' binding with human aFGF and bFGF

Preclinical Safety Evaluation of Oral Drug of Human Granulocyte-Macrophage Colony-Stimulating Factor Expressed in Silkworm Pupae As Bioreactor

Preclinical Safety Evaluation of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Rhesus Monkey

Transfection of basic fibroblast growth factor gene into rabbit bone marrow mesenchymal stem cells

The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability

Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein in Vivo.

Continuous Administration of Basic Fibroblast Growth Factor (FGF-2) Accelerates Bone Induction on Rat Calvaria— An Application of a New Drug Delivery System